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Conclusions: Long-course chemo-radiotherapy with 
simultaneous integrated boost is safe in the treatment of 
rectal cancer patients. Patients presenting more pronounced 
and/or several toxicity showed a significant trend toward a 
better TRG. Immunological local reactions could potentially 
explain these results, and should be further explored. 
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Purpose/Objective: UK IMRT anal cancer treatment uses 
large fields to uninvolved nodal groups (40Gy) with 
simultaneous integrated boost to the primary tumour (50.4Gy 
T1/T2; 53.2Gy T3/T4) and involved nodes (50.4Gy). With a 
simple bony match online, iliac nodes are well covered and 
the margins required are well documented, however the 
margins for prophylactic inguinal nodes (pIN) and primary 
tumour are not well established as data from daily imaging 
are limited; these form the focus of this study. 
Materials and Methods: Anal cancer patients treated at a 
single institution under current UK IMRT guidelines were 
screened; 11 consecutive inguinal node negative patients 
were studied. Supine treatment comprised 28 fractions with 
daily imaging: CBCT fractions 1-5, 10, 15, 20 and 25; 
orthogonal kV imaging all other fractions. 
99 CBCT’s were re-matched automatically to the planning 
CT. A bony match was performed using a clipbox 
encompassing the bony pelvis. Re-matches were performed 
within the same clipbox using the clinician defined tumour 
(GTVA) as a region of interest (ROI), then repeated with the 
pIN ROI. Accuracy of auto-matches were assessed visually to 
ensure clinical relevance. 
Bony match values were subtracted from the GTVA and pIN 
measurements to evaluate differences in the optimal 
treatment position for the tumour or the nodes relative to a 
simple bony match. Margins were calculated using van Herk’s 
recipe.  
Results: Differences (mm) between GTVA/ bony matches 
were larger than inguinal/ bony matches in all axes ( lat -3.1 
to 4.2; -2 to 1.5, vert- 6.9 to 12.7; -3.6 to 2.9, long -13.3 to 
17.2; -8.5 to 7.3 in GTV and pIN respectively). This was 
statistically significant in the long axis (p<0.05) shown in 
Fig.1. GTVA had consistently larger systematic and random 
errors than pIN, reflected in the margin calculations (mm): 
GTVA lat 2.8, long 9.8, vert 5.8; pIN lat 1.5, long 3.1, vert 
3.1. 
Conclusions: With a simple bony match, the margin around 
pIN can be reduced to 1.5mm laterally and 3.1mm in all 
other directions potentially reducing toxicity to the groin, 
genitalia and bladder. 
The GTVA to PTV margin incorporates microscopic disease, 
the motion of the soft tissues of the anus which can be 
affected by tumour size, location, bowel filling and BMI; and 
the set up error. The margin reported in this study covers set 
up error and soft tissue motion of the anus. An individualised 
margin incorporating these factors can be calculated and 
applied during the treatment course with the aim of reducing 
toxicity in adjacent organs such as vagina, bladder and penile 
bulb.  
Further investigation is warranted to demonstrate reduced 
toxicities with these strategies. 
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Purpose/Objective: Multidisciplinary clinics (MDCs) offer 
patients an initial evaluation by all three oncologic 
specialists, radiologists, pathologists, and others. The costs 
and overall value (defined as quality divided by costs) of care 
in MDCs are not well-described. For patients with pancreatic 
cancer, we compared direct care costs, patient retention 
rates, patient phone calls with symptoms, patient ED visits 
with symptoms, and survival outcomes for patients treated in 
a pancreatic MDC to patients evaluated outside of the MDC. 
Materials and Methods: Two cohorts of patients with 
pancreatic cancer seen at our institution were analyzed and 
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compared retrospectively: patients evaluated in a pancreatic 
MDC versus outside the MDC. Demographics, region of origin, 
disease stage, and patient retention rates (defined as >3 
encounters for pancreatic cancer), telephone encounters, 
and ED visit counts were collected using electronic health 
records. Cost information was obtained using claims data, 
and compared using Fisher’s Exact Tests. Logistic regression 
compared retention rates between the groups, correcting for 
region of origin, demographics, and disease stage. Cox 
proportional hazard models were used to calculate hazard 
ratios of death. Kaplan-Meier curves compared long-term 
survival between the two groups. 
Results: Between 2008-2010, 252 consecutive MDC patients 
were compared to 764 non-MDC patients (total N = 1100). A 
greater percentage of MDC patients traveled from non-
adjacent states (49 vs 23%, p<0.001) and had more advanced 
disease stages (10, 25, and 23% of MDC patients with 
borderline resectable, locally advanced and metastatic 
disease, respectively, versus 5, 9, and 18% of non-MDC). 
Multivariate analysis revealed that MDC patients had 2.816 
times the odds of being retained over non-MDC patients 
(p<0.001). Total charges per patient were higher for non-MDC 
patients than MDC patients and all cost subcategories were 
higher for non-MDC vs MDC patients except for outpatient 
charges (Table 1). The non-MDC group had a higher adjusted 
hazard ratio for death than the MDC group, trending toward, 
but not reaching statistical significance (HR 1.182, p=0.117). 
The MDC also had a lower rate of symptom telephone calls 
(SS) and ED visits (although NS) than the non-MDC group. At 
three years, overall survival was 20% for both MDC and non-
MDC patients (log rank p=0.845). 
Conclusions: Adjusted for region of origin, MDC patients 
were more likely to continue their care at Johns Hopkins, 
suggesting higher patient satisfaction. Total costs per patient 
were lower for MDC patients, even with a greater retention 
rate. Outpatient costs were higher for MDC patients, 
suggesting that greater outpatient engagement can supplant 
more costly inpatient encounters. Because adverse 
downstream encounters were less frequent, survival 
outcomes were at least similar for both groups, and MDC 
patients had lower costs, these data suggest multidisciplinary 
models offer care of higher value for patients with pancreatic 
cancer.  
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Purpose/Objective: Neoadjuvant chemoradiotherapy 
(NACRT) followed by surgery is the standard of care for 
locally advanced carcinoma rectum. Reassessment for surgery 
is done with an MRI scan 6-8 weeks after completion of 
NACTRT.  
The patients in whom the tumor is still inoperable, are 
usually offered palliative chemotherapy. Many oncologists 
advocate waiting upto 12 weeks for a response assessment 
MRI before declaring the disease unresectable, citing a 
possibility of delayed tumour response to radiotherapy. At 
our institute we treated these patients with further 4cycles 
of chemo and reassessed them for operability.  
Materials and Methods: Patients with locally advanced 
carcinoma rectum assessed to have unresectable disease on 
MRI at presentation received neoadjuvant radiation to a dose 
of 50 Gy in 1.8 to 2 Gy daily fractions with concurrent 
capecitabine chemotherapy 825 mg/m2 daily. A follow up MRI 
was done 6 weeks after completion of NACRT and assessed in 
a joint multidisciplinary meeting. Those with persisting 
unresectable local disease were planned for 4 cycles of 
chemotherapy followed by reassessment imaging for 
resectability. We present the results of the patients with 
poor response to NACTRT having further treated by the 
chemotherapy.  
Results: From Jan 2013 till September 2014, 39 patients with 
unresectable rectal cancer recieving NACRT were still found 
to have unresectable disease on MRI. They were planned for 
further chemotherapy with FOLFIRINOX or FOLFOX based 
regimens. Thirty six patients completed at least 4 cycle of 
chemotherapy and one patient defaulted. At the time of 
submission of this abstract, 24 patients had good regression 
of disease which was evident on MRI and 17 (45%) patients 
underwent R0 resection. Seven patients who still had 
unresectable disease and 2 which developed distant 
metastasis were given further palliative chemotherapy. Seven 
patients are scheduled for reassessment after followup 
imaging. One patient was lost to follow-up and 1 died due to 
sepsis. Two patients had complete pathological response. 
Among the 17 successfully operated patients, 8 had received 
FOLFIRINOX while 1 had received FOLFOX and 8 patients 
received CAPOX chemotherapy.  
Conclusions: Achieving margin negative resection in these 
patients is an encouraging starting point for further research 
in this subset. Whether this continued decrease in primary 
tumour volume can be attributed to delayed response to 
radiotherapy or addition of further chemotherapy, or both, is 
yet to be ascertained. Hence for patients with advanced local 
disease not yet in palliative stage, further intensive 
chemotherapy with clinicoradiological follow-up should be 
done to facilitate successful surgical resection.  
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